{"id":58840,"date":"2026-03-05T13:45:14","date_gmt":"2026-03-05T05:45:14","guid":{"rendered":"https:\/\/flcube.com\/?p=58840"},"modified":"2026-03-05T13:45:15","modified_gmt":"2026-03-05T05:45:15","slug":"konruns-pharmas-kc1036-wins-nmpa-approval-dual-target-vegfr2-axl-inhibitor-enters-io-combination-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58840","title":{"rendered":"Konruns Pharma&#8217;s KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\/AXL Inhibitor Enters IO Combination Trials"},"content":{"rendered":"\n<p><strong>Beijing Konruns Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/603590:SHA\">SHA:\u202f603590<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>clinical trials<\/strong> for <strong>KC1036<\/strong>, its <strong>Class\u202f1 innovative small\u2011molecule drug<\/strong>, in <strong>combination with PD\u20111\/PD\u2011L1 therapies<\/strong> for <strong>recurrent or metastatic advanced solid tumors<\/strong>. The <strong>dual\u2011target inhibitor<\/strong> (VEGFR2 + AXL) aims to <strong>enhance immunotherapy efficacy<\/strong> through <strong>vascular normalization<\/strong> and <strong>immune response improvement<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Beijing Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>KC1036<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Class\u202f1 innovative small molecule; dual\u2011target inhibitor<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td><strong>VEGFR2<\/strong> + <strong>AXL<\/strong><\/td><\/tr><tr><td><strong>IP Status<\/strong><\/td><td>Global intellectual property rights (independently developed)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA clinical trial approval<\/td><\/tr><tr><td><strong>Combination Strategy<\/strong><\/td><td>PD\u20111\/PD\u2011L1 inhibitors<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Recurrent or metastatic advanced solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-dual-target-synergy\">Mechanism of Action \u2013 Dual\u2011Target Synergy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target<\/th><th>Inhibition Effect<\/th><th>Therapeutic Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>VEGFR2<\/strong><\/td><td>Strong vascular targeting<\/td><td>Suppresses tumor cell growth; normalizes tumor vasculature<\/td><\/tr><tr><td><strong>AXL<\/strong><\/td><td>Receptor tyrosine kinase blockade<\/td><td>Improves host anti\u2011tumor immune response; prevents tumor immune escape<\/td><\/tr><tr><td><strong>Combined Effect<\/strong><\/td><td>VEGFR2 + AXL dual blockade<\/td><td><strong>Enhanced immunotherapy efficacy<\/strong> via vascular normalization + immune activation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IO Combination Rationale:<\/strong> The <strong>PD\u20111\/PD\u2011L1 combination strategy<\/strong> addresses <strong>primary resistance<\/strong> to immunotherapy in <strong>&#8220;cold&#8221; tumors<\/strong>; KC1036&#8217;s <strong>VEGFR2\/AXL inhibition<\/strong> converts <strong>immune\u2011excluded microenvironments<\/strong> to <strong>immune\u2011permissive states<\/strong>, potentially <strong>expanding IO responder populations<\/strong>.<\/li>\n\n\n\n<li><strong>AXL Differentiation:<\/strong> While <strong>VEGFR inhibitors<\/strong> (sunitinib, axitinib) are established, <strong>AXL targeting<\/strong> is <strong>novel in IO combinations<\/strong>; AXL drives <strong>tumor cell migration, immune suppression, and therapy resistance<\/strong>\u2014blockade may <strong>sensitize resistant tumors<\/strong> to checkpoint inhibitors.<\/li>\n\n\n\n<li><strong>Global IP Position:<\/strong> <strong>Full global intellectual property rights<\/strong> enable <strong>unencumbered worldwide development<\/strong> and <strong>out\u2011licensing flexibility<\/strong>, positioning Konruns for <strong>multinational partnership<\/strong> or <strong>independent US\/EU regulatory submissions<\/strong>.<\/li>\n\n\n\n<li><strong>Solid Tumor Breadth:<\/strong> The <strong>advanced solid tumor indication<\/strong>\u2014spanning <strong>lung, liver, gastric, and other malignancies<\/strong>\u2014provides <strong>basket trial flexibility<\/strong> to identify <strong>responsive tumor types<\/strong> and <strong>biomarker\u2011selected populations<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>IO Combination Market<\/strong><\/td><td>~\u202f$50\u202fbillion globally; VEGF\/VEGFR inhibitors + PD\u20111 standard in renal cell carcinoma, hepatocellular carcinoma; AXL addition represents next\u2011gen approach<\/td><\/tr><tr><td><strong>AXL Inhibitor Landscape<\/strong><\/td><td>Berzosertib (Merck KGaA), bemcentinib (BerGenBio) in development; KC1036&#8217;s dual VEGFR2\/AXL profile may offer superior efficacy vs. single\u2011target AXL inhibitors<\/td><\/tr><tr><td><strong>China IO Innovation<\/strong><\/td><td>Domestic PD\u20111 inhibitors (sintilimab, camrelizumab, tislelizumab) dominate; KC1036 combination addresses <strong>resistance mechanisms<\/strong> and <strong>differentiation needs<\/strong><\/td><\/tr><tr><td><strong>Konruns Pipeline Depth<\/strong><\/td><td>KC1036 anchors <strong>oncology franchise<\/strong>; VEGFR2\/AXL platform supports <strong>additional indications<\/strong> (angiogenesis\u2011dependent tumors, fibrotic diseases)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase I\/II enrollment, IO combination safety, and efficacy outcomes for KC1036. Actual results may differ due to risks including additive toxicity with PD\u20111 inhibitors, competitive VEGFR\/AXL program advancement, and biomarker selection complexity.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/603590_20260305_S974.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603590_20260305_S974.\"><\/object><a id=\"wp-block-file--media-658b253c-119e-4474-9c80-892037176cfc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/603590_20260305_S974.pdf\">603590_20260305_S974<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/603590_20260305_S974.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-658b253c-119e-4474-9c80-892037176cfc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China&#8217;s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,2984,1532],"class_list":["post-58840","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-konruns-pharmaceutical","tag-sha-603590"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Konruns Pharma&#039;s KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\/AXL Inhibitor Enters IO Combination Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China&#039;s National Medical Products Administration (NMPA) has approved clinical trials for KC1036, its Class\u202f1 innovative small\u2011molecule drug, in combination with PD\u20111\/PD\u2011L1 therapies for recurrent or metastatic advanced solid tumors. The dual\u2011target inhibitor (VEGFR2 + AXL) aims to enhance immunotherapy efficacy through vascular normalization and immune response improvement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58840\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Konruns Pharma&#039;s KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\/AXL Inhibitor Enters IO Combination Trials\" \/>\n<meta property=\"og:description\" content=\"Beijing Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China&#039;s National Medical Products Administration (NMPA) has approved clinical trials for KC1036, its Class\u202f1 innovative small\u2011molecule drug, in combination with PD\u20111\/PD\u2011L1 therapies for recurrent or metastatic advanced solid tumors. The dual\u2011target inhibitor (VEGFR2 + AXL) aims to enhance immunotherapy efficacy through vascular normalization and immune response improvement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58840\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T05:45:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T05:45:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58840#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58840\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Konruns Pharma&#8217;s KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\\\/AXL Inhibitor Enters IO Combination Trials\",\"datePublished\":\"2026-03-05T05:45:14+00:00\",\"dateModified\":\"2026-03-05T05:45:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58840\"},\"wordCount\":441,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Konruns Pharmaceutical\",\"SHA: 603590\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58840#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58840\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58840\",\"name\":\"Konruns Pharma's KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\\\/AXL Inhibitor Enters IO Combination Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-05T05:45:14+00:00\",\"dateModified\":\"2026-03-05T05:45:15+00:00\",\"description\":\"Beijing Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China's National Medical Products Administration (NMPA) has approved clinical trials for KC1036, its Class\u202f1 innovative small\u2011molecule drug, in combination with PD\u20111\\\/PD\u2011L1 therapies for recurrent or metastatic advanced solid tumors. The dual\u2011target inhibitor (VEGFR2 + AXL) aims to enhance immunotherapy efficacy through vascular normalization and immune response improvement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58840#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58840\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58840#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Konruns Pharma&#8217;s KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\\\/AXL Inhibitor Enters IO Combination Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Konruns Pharma's KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\/AXL Inhibitor Enters IO Combination Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China's National Medical Products Administration (NMPA) has approved clinical trials for KC1036, its Class\u202f1 innovative small\u2011molecule drug, in combination with PD\u20111\/PD\u2011L1 therapies for recurrent or metastatic advanced solid tumors. The dual\u2011target inhibitor (VEGFR2 + AXL) aims to enhance immunotherapy efficacy through vascular normalization and immune response improvement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58840","og_locale":"en_US","og_type":"article","og_title":"Konruns Pharma's KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\/AXL Inhibitor Enters IO Combination Trials","og_description":"Beijing Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China's National Medical Products Administration (NMPA) has approved clinical trials for KC1036, its Class\u202f1 innovative small\u2011molecule drug, in combination with PD\u20111\/PD\u2011L1 therapies for recurrent or metastatic advanced solid tumors. The dual\u2011target inhibitor (VEGFR2 + AXL) aims to enhance immunotherapy efficacy through vascular normalization and immune response improvement.","og_url":"https:\/\/flcube.com\/?p=58840","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-05T05:45:14+00:00","article_modified_time":"2026-03-05T05:45:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58840#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58840"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Konruns Pharma&#8217;s KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\/AXL Inhibitor Enters IO Combination Trials","datePublished":"2026-03-05T05:45:14+00:00","dateModified":"2026-03-05T05:45:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58840"},"wordCount":441,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Konruns Pharmaceutical","SHA: 603590"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58840#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58840","url":"https:\/\/flcube.com\/?p=58840","name":"Konruns Pharma's KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\/AXL Inhibitor Enters IO Combination Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-05T05:45:14+00:00","dateModified":"2026-03-05T05:45:15+00:00","description":"Beijing Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China's National Medical Products Administration (NMPA) has approved clinical trials for KC1036, its Class\u202f1 innovative small\u2011molecule drug, in combination with PD\u20111\/PD\u2011L1 therapies for recurrent or metastatic advanced solid tumors. The dual\u2011target inhibitor (VEGFR2 + AXL) aims to enhance immunotherapy efficacy through vascular normalization and immune response improvement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58840#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58840"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58840#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Konruns Pharma&#8217;s KC1036 Wins NMPA Approval \u2013 Dual\u2011Target VEGFR2\/AXL Inhibitor Enters IO Combination Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58840"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58840\/revisions"}],"predecessor-version":[{"id":58842,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58840\/revisions\/58842"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}